Format

Send to

Choose Destination
Gan To Kagaku Ryoho. 1985 Jan;12(1):77-85.

[Phase III study of bestatin in patients with malignant skin tumors. (1) Malignant melanoma].

[Article in Japanese]

Abstract

As a co-operative study involving 18 medical research institutions, we have made a randomized, controlled study (phase III study) of Bestatin in the treatment of malignant melanoma (stage Ib, II) over the last 4 years. The results were as follows; Bestatin significantly prolonged disease-free intervals by 9-20 month. Bestatin significantly prolonged survival periods by 10-16 months. Side effects of Bestatin, chiefly comprising of reversible gastro-intestinal disturbances, were observed in 7.1% of Bestatin-treated cases. These findings suggest that Bestatin is a very useful agent for treating for stage Ib and II malignant melanomas.

PMID:
3881086
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center